Blood glucose monitoring equipment market research analysis

According to the medical network of June 20th, the blood glucose monitoring market has a huge space capacity. Continuing policies favor the import substitution of domestic equipment. At the same time, under the background of the new economy, a series of new service models have emerged in the traditional blood glucose monitoring industry.

First, huge market space capacity, low domestic market penetration rate

According to the statistics of China Diabetes Association, the number of diabetic patients in China has reached 114 million, the prevalence rate is about 9.7%, and the prevalence rate of blood glucose monitoring systems is less than 10%, which is far behind the developed countries.

Figure 1 Comparison of blood glucose meter permeability

Source: Biological Exploration, Fortune Securities

Relevant data show that the current global blood glucose monitoring system has a capacity of more than 20 billion U.S. dollars. In 2016, China's blood glucose testing market was about 6 billion yuan, and its penetration rate was only 20%, far below the average level.

Second, policies continue to be positive and promote the import substitution of domestic equipment

During the 12th Five-Year Plan period, the Ministry of Science and Technology promulgated the "12th Five-Year Special Plan for Medical Device Technology Industry." In accordance with the planning requirements, it actively developed POCT on the field of diagnosis.

In 2017, the General Office of the Ministry of Science and Technology released the “13th Five-Year Plan for Scientific and Technological Innovation in Medical Devices”, clearly stating that during the “Thirteenth Five-Year Plan” period, we will vigorously develop an intelligent on-site rapid detection system, including the development of integrated dry chemistry analyzers, and automation. Rapid Immune Detector, Pocket Sequencer, Portable Nucleic Acid Detector and Associated Detection Reagents and Quality Controls; Development of high-sensitivity on-site rapid detection technology and supporting reagents for non-invasive collection of samples. Launch of non-invasive blood glucose detector, wearable in vitro detection technology and Equipment research.

The policy continued to be positive, promoted the technical upgrading of domestic blood glucose monitoring products, improved competitiveness, and changed the long-term import status of domestic high-end products.

Third, Roche and Johnson & Johnson currently dominate the market competition pattern of two major foreign brands. There are uncertainties in the future.

Judging from the current market competition pattern of blood glucose monitoring, foreign brands strongly dominate the market competition, with Roche and Johnson accounting for more than 50%.

Figure 2 The competition pattern of blood glucose monitoring market

Among them, 2017 Roche's financial report data shows that the sales of diagnostic services increased by 5%. From the perspective of major sales regions, the Chinese market ranked first in the major sales regions with a 21% share.

In addition, according to a Reuters survey, Johnson & Johnson Diabetes Care's revenue has been declining since 2012. In the first nine months of 2017, sales fell 7.7% year-on-year. At the same time, there were reports that Johnson & Johnson had included three from domestic companies. Buyers including Connaught have negotiated sales of the Diabetes business, and in 2018 Johnson & Johnson announced the receipt of leading private investment. enterprise A quotation for the acquisition of Johnson & Johnson's LifeScan blood glucose meter business has a transaction volume of approximately US$2.1 billion. Therefore, whether the future blood glucose meter business will be divested from Johnson & Johnson will change the current market competition pattern of blood glucose monitoring.

With the continuous application of the Internet, big data, and cloud computing technologies, new product and service models have emerged in traditional blood glucose monitoring equipment to form a new economy. The main products or services include non-invasive blood glucose meters, smart blood glucose monitors, cloud platform applications, etc. .

In terms of intelligent cloud platforms, Johnson & Johnson Blood Glucose Meters teamed up with Internet technology giant Huawei to build a 'Home Blood Glucose Management Cloud Platform' to allow more patients with diabetes to easily and quickly understand their blood glucose status. In addition, Sino Biosciences established hospitalized blood glucose management. New solutions -hospital Blood glucose management system. This system consists of smart blood glucose meter and built-in APP, blood glucose management software, blood glucose database, interface software and bar code system. Nurses can use smart blood glucose meter to confirm patients, test blood sugar and upload data, and use blood sugar management software to manage patients , Manage blood glucose meter controls, print forms. At the same time, doctors can use smart blood glucose meters to view blood glucose charts.

Sannuo Biosensing Co., Ltd. is a company dedicated to the use of bio-sensing technology for R&D, production, sales, and rapid detection of chronic diseases. disease High-tech products of the company.

As a national high-tech industrialization demonstration project of biomedical engineering, it has won the support of the National Innovation Fund for many times, and took the lead in adopting the ISO 13485 quality management system certification and the European Union CE certification. In January 2016, it participated in the acquisition of Trividia Health Inc. (formerly the United States Niplo Diagnostics Co., Ltd.) became the world's sixth largest blood glucose meter company and entered the global blood glucose meter leading camp.

Headquartered in Shanghai, China, it has seven R&D centers and five major production bases in San Diego, Tuttlingen, Germany, Taipei, Beijing, Shanghai, Nanjing, Suzhou and Danyang, and has established a number of offices throughout the world. Complete research and development, production, marketing and service network. In the context of the Internet, Diving is based on professional clinical medicine, providing patients with remote chronic disease management, remote medical diagnosis and other cloud medical services, and subverting traditional medical models.

Established in 1995, they successively passed the three major international certifications of the US FDA, European CE, and ISO13485. They were selected for the Forbes China Potential 100 List for three consecutive years.

Relying on China and the United States Talent With technological advantages, a complete R&D, production and sales industrialization system has been established in the field of bio-diagnosis, and products cover in vitro diagnostic reagents. medical instruments , Medical electronics three major industries, successfully developed Ai Ke series of blood glucose meters, urine analyzers, dry biochemical analyzers, hemoglobin analyzers, blood lipid analyzers and other medical devices and corresponding detection reagents, PCR detection reagents, enzyme-linked immunosorbent assay reagents More than 100 kinds of rapid diagnostic products such as colloidal gold detection reagents, 80 Chinese SFDA medical device certificates, 365 models of 80 products have obtained European CE certification, and the products are sold in more than 140 countries and regions in the world.